| Document Date: 2014-11-03 11:26:11
Open Document File Size: 31,44 KBShare Result on Facebook
City Denver / Osaka / London / / Company ViiV Healthcare / Shionogi-ViiV Healthcare LLC / Shionogi & Co. Ltd. / Corporate Communications Shionogi & Co. Ltd. / / Country Japan / United States / Canada / / Event Business Partnership / FDA Phase / / / IndustryTerm treatment of HIV / foreign healthcare reforms / with respect to product / / MedicalCondition HIV / / MedicalTreatment antiretroviral therapy / / Organization FDA / European Union / / Person Isao Teshirogi / Dominique Limet / / / Position President & CEO / Chief Executive Officer / / Product Tivicay® (dolutegravir) / Tivicay® / Integrase Inhibitor Tivicay® (dolutegravir) / / PublishedMedium Antimicrobial Agents and Chemotherapy / / Technology Chemotherapy / /
SocialTag |
Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I